Sartorius Stedim Biotech
Universal Registration Document
Including the Annual Financial Report
2024
“In 2024, Sartorius Stedim Biotech has successfully navigated the challenges that the entire life science industry continued to face: both inventory destocking and muted investment activities at customers continued for longer than anticipated. Under these conditions, Sartorius Stedim Biotech performed better than the market segment, proving its strong competitive position. While we shouldn’t focus too much on individual quarters, it’s encouraging to see an increasingly positive trend with business picking up significantly during the second half of the year and especially in the last quarter.”
“The industry is gradually returning to its robust, structural growth trend. For 2025, however, we remain cautious and assume that market growth is still likely to be below the long-term average for now. Against this backdrop, we expect moderate revenue growth above market level and increasing profitability for our company.”
Sales revenue
€2,780.0m
in constant FX: 0.6%
Underlying EBITDA
€779.0m
-0.8%
Order intake
€2,781.6m
in constant FX: 12.9%
Employees
9,901
-761
Market capitalization
~€18.4bn
-16.7%
Group Business Development
After the very volatile development of previous years due to the pandemic, the business situation at Sartorius Stedim Biotech stabilized in 2024 despite a difficult environment in the entire life science industry that lasted longer than expected. In particular, the second half of the year and especially the last quarter showed a significant improvement compared to the first half. The trend in the consumables business was increasingly positive, as most customers have meanwhile reached their target inventory levels, some of which have been revised downwards several times, and are gradually returning to an order level that corresponds to their production activities. Sales revenue from products for advanced therapies also continued to grow at an above average rate. In contrast, business with bioprocessing equipment remained muted, although customers continued to demand innovative systems, for example in the area of process intensification.